Collegium Pharmaceutical (COLL) Non-Current Assets (2014 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Non-Current Assets of $906.3 million for Q1 2026, down 17.9% year-over-year from $1.1 billion in Q1 2025, and down 6.13% quarter-over-quarter from $965.4 million in Q4 2025.
Collegium Pharmaceutical (COLL) Non-Current Assets (2014 - 2026) Analysis & Trends
Collegium Pharmaceutical's Non-Current Assets history runs 13 years deep, the most recent figure standing at $906.3 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 17.9% year-over-year to $906.3 million; the TTM figure through Mar 2026 stood at $3.9 billion (down 2.76% YoY), while the FY2025 annual figure was $965.4 million, down 18.28% from the prior year.
- Non-Current Assets for Q1 2026 stood at $906.3 million, down from $965.4 million in the prior quarter.
- The five-year high for Non-Current Assets was $1.2 billion in Q3 2024, with the low at $543.2 million in Q2 2024.
- The 5-year median for Non-Current Assets is $835.8 million (2022), against an average of $847.7 million.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets surged 152.32% in 2022, then slipped 19.72% in 2024.
- Collegium Pharmaceutical's Non-Current Assets stood at $754.1 million in 2022, then fell by 19.68% to $605.7 million in 2023, then jumped by 95.03% to $1.2 billion in 2024, then retreated by 18.28% to $965.4 million in 2025, then retreated by 6.13% to $906.3 million in 2026.
- Business Quant data shows COLL's Non-Current Assets at $906.3 million in Q1 2026, $965.4 million in Q4 2025, and $993.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 2.96 Bn |
| 10 | Collegium Pharmaceutical | 889.75 Mn | 740.43 Mn | 110.29 Mn | 1.53 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.53 Bn |
| Mar 31, 2026 | 906.29 Mn |
| Dec 31, 2025 | 965.42 Mn |
| Sep 30, 2025 | 993.46 Mn |
| Jun 30, 2025 | 1.04 Bn |
| Mar 31, 2025 | 1.10 Bn |
| Dec 31, 2024 | 1.18 Bn |
| Sep 30, 2024 | 1.19 Bn |
| Jun 30, 2024 | 543.19 Mn |
| Mar 31, 2024 | 574.99 Mn |
| Dec 31, 2023 | 605.71 Mn |
| Sep 30, 2023 | 640.49 Mn |
| Jun 30, 2023 | 676.62 Mn |
| Mar 31, 2023 | 716.00 Mn |
| Dec 31, 2022 | 754.14 Mn |
| Sep 30, 2022 | 795.72 Mn |
| Jun 30, 2022 | 835.80 Mn |
| Mar 31, 2022 | 882.50 Mn |
| Dec 31, 2021 | 376.53 Mn |
| Sep 30, 2021 | 378.57 Mn |